ASH Ashland Global Holdings Inc.

Ashland expands pharmaceutical plant for Aquarius™ tablet coatings and commissions new microbial protection capability in Brazil, demonstrating strategy to globalize, innovate, and invest

Ashland expands pharmaceutical plant for Aquarius™ tablet coatings and commissions new microbial protection capability in Brazil, demonstrating strategy to globalize, innovate, and invest

Increased production capacity and market presence expected to drive competitive position and organic growth; follows previous investments in Ireland and China

Wilmington, Del., April 01, 2025 (GLOBE NEWSWIRE) -- Ashland has completed a 10-million-dollar expansion of its pharmaceutical manufacturing plant in Cabreúva, Brazil and will celebrate the occasion with a ribbon-cutting ceremony on April 4, 2025.

The investment significantly expands Ashland’s pharmaceutical footprint in the region and capabilities to meet increasing market demand for coated tablets in Latin America and Brazil. Between 2019 and 2023 the consumption of coated tablets in Latin America had an average growth of 4.3 percent per year, while Brazil has reached growth of 5.7 percent per year+

The investment also includes the modernization of equipment for microbial protection in personal care applications at the Research and Development (R&D) laboratory of the company's Technical Center in São Paulo and follows the company’s previous investments to expand their bioresorbable polymers facility in Mullingar, Ireland and biofunctionals R&D lab in Shanghai, China.  

“Our focused actions continue to demonstrate Ashland’s strategies to globalize, innovate and invest as a means of driving superior differentiation for customers and increase shareholder value,” said Guillermo Novo, chair and chief executive officer, Ashland. “The investments we have made in Cabreúva and São Paulo are supporting the globalization of our expertise in tablet coatings and microbial protection. They ensure even more innovation, collaboration and technical support for Ashland customers.”

The new state-of-the-art equipment enhances Ashland’s capabilities in tablet coatings application, color matching, stability and quality evaluation. Through enhancements to the R&D lab, Ashland can offer customized solutions to industry needs, and innovative solutions with ultra-high solids coatings, moisture protection, odor and flavor masking, and modified release systems. To ensure optimal performance, local Ashland employees underwent specialized training at the company’s headquarters in the United States and with equipment manufacturers.

“Our investments are focused on meeting growing market demand in Brazil and Latin America with more efficiency and technology,” said Alessandra Faccin, senior vice president and general manager, life sciences, Ashland. “The new plant accommodates high-performance production, and offers our customers differentiated technical support from formulation design to industrial scale, enabling new innovations and organic growth."

“In personal care, we are excited to commission the local production of microbial protection products in Brazil,” said Hamilton Oliveira Junior, general manager, Latin America, personal care, Ashland. “This investment is a key part of our globalization strategy and will serve as a source of differentiation as we innovate and position supply closer to our customers.” 

"We believe this is the ideal time to expand our operations and strengthen our presence in the region,” said Brenda Rangel, regional leader, Latin America, Ashland. “The pharmaceutical and personal care industries are in full evolution, and Ashland will continue being a strategic innovation partner for the industry, offering high-performance products and services."

To further institute organic growth for Ashland as well as customers, in 2023, Ashland introduced seven new platform technologies aligned to the company’s core that extend to secondary markets with new and differentiated capabilities.  Ashland’s platform solutions bring “new to the world,” sustainable innovations, offering choice to customers and consumers in personal care, pharmaceuticals, coatings and more, enabling customers to reshape global megatrends and respond to various regulatory landscapes worldwide. Ashland has introduced several patented innovations derived from the Transformed Vegetable Oils and Super Wetters platforms with more expected this year under additional platform technologies.  

To learn more, visit:



About Ashland

Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social, and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical. Approximately 3,200 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative, and elegant solutions to complex problems for customers in more than 100 countries. Visit and to learn more.

+. data from IQVIA

Trademark, Ashland, or its subsidiaries, registered in various countries.

Investor Relations Ashland:Media Relations Ashland:
William C. Whitaker Carolmarie C. Brown
+1 (614) 790-2095+1 (302) 995-3158



Media Relations Ashland Brazil:
Cristina Friedman
29

Attachment



EN
01/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ashland Global Holdings Inc.

 PRESS RELEASE

Ashland expands pharmaceutical plant for Aquarius™ tablet coatings and...

Ashland expands pharmaceutical plant for Aquarius™ tablet coatings and commissions new microbial protection capability in Brazil, demonstrating strategy to globalize, innovate, and invest Increased production capacity and market presence expected to drive competitive position and organic growth; follows previous investments in Ireland and China Wilmington, Del., April 01, 2025 (GLOBE NEWSWIRE) -- Ashland has completed a 10-million-dollar expansion of its pharmaceutical manufacturing plant in Cabreúva, Brazil and will celebrate the occasion with a ribbon-cutting ceremony on April 4, 202...

 PRESS RELEASE

Ashland to host 2025 Innovation Day for analysts and investors

Ashland to host 2025 Innovation Day for analysts and investors WILMINGTON, Del., March 28, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) is hosting an Innovation Day for analysts and investors at the company’s Bridgewater, New Jersey facility, Thursday, May 29, 2025. The event will showcase the enhanced capabilities and expanded applications of Ashland's scalable technology platforms. Registration is required, with options to attend via live webcast or in person. Participants will join Ashland’s executive and senior technology team for an in-depth review of the latest developments an...

 PRESS RELEASE

Ashland completes sale of Avoca business to Mane

Ashland completes sale of Avoca business to Mane Wilmington, Del., March 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that it has completed the sale of its Avoca business to Mane effective March 14, 2025. Financial terms of the transaction were not disclosed. The Avoca business supplies sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin.  The Avoca business line represents the last entity from Ashland’s previous acquisition of Pharmachem. “The Avoca business is a s...

Ashland Inc: 2 directors

Two Directors at Ashland Inc bought/maiden bought 34,444 shares at between 64.000USD and 64.240USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch